MarketPulse

diabetic macular edema

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026

EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market With First Eye Drop Therapy as ARVO Data Show Unmet Need

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market Opportunity as Study Reveals 60% Patient Non-Treatment Rate

Oculis-backed research reveals significant unmet needs in diabetic macular edema treatment, with 60% of patients remaining untreated due to invasive therapies.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 Amid Key DME Trial Readout

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.
OCSOCSAWclinical trialsdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 as OCS-01 Phase 3 Data Nears

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.
OCSOCSAWPhase 3 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Bioage Labs, Inc.

BioAge's BGE-102 Shows Best-in-Class Inflammation Reduction in Phase 1 Trial

BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.
BIOAPhase 1 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Gears Up for Pivotal 2026 With Six Major Clinical Readouts Planned

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.
OCSOCSAWclinical trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

EyePoint Grants Stock Options to New Hires as DURAVYU Phase 3 Trials Advance

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.
EYPTPhase 3 trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

EyePoint Sets March 4 Earnings Call as Pipeline Advances Toward Key Milestones

EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.
EYPTbiopharmaceuticalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO

EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology